Skip to main content

A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)

Trial Status: Closed to Accrual

A phase 1, dose escalation study of evorpacept (ALX148) in patients with advanced solid tumors and lymphoma

Inclusion Criteria

  • Histological or cytological diagnosis of advanced/metastatic solid tumor malignancy; or relapsed or refractory Non-Hodgkin lymphoma for whom no standard therapy is available..
  • Adequate Bone Marrow Function.
  • Adequate Renal & Liver Function.
  • Adequate Performance Status

Exclusion Criteria

  • Patients with known symptomatic CNS metastases or lepotomeningeal disease requiring steroids.
  • Previous high-dose chemotherapy requiring allogenic stem cell rescue.
  • Prior treatment with a CD47 or signal regulatory protein (SIRP) alpha targeting agent.


University of Colorado Hospital


New Haven
Yale University
Status: ACTIVE


Brigham and Women's Hospital
Status: ACTIVE
Dana-Farber Cancer Institute
Status: ACTIVE
Contact: Frank Stephen Hodi
Phone: 617-632-5053
Massachusetts General Hospital Cancer Center
Status: ACTIVE
Contact: Justin F. Gainor
Phone: 617-724-4000


Fred Hutch / University of Washington Cancer Consortium

This phase 1 clinical study (AT148001) is an open-label, multi-center, multiple-dose,

dose-escalation, safety, PK, and PD study of evorpacept (ALX148). The phase 1 protocol will

have 2 parts: a single agent dose escalation phase (Part 1) and a combination therapy phase

(Part 2). Part 2 will include an initial dose escalation portion followed by a dose expansion

portion. Approximately 184 adult patients are expected to be enrolled in the study.

Trial Phase Phase I

Trial Type Treatment

Lead Organization
ALX Oncology Inc.

  • Primary ID AT148001
  • Secondary IDs NCI-2017-00378
  • ID NCT03013218